TickerTain — Make Analysis Fun Again

▶ 3:00 · Vaccines · Vaccines offer highest ROI in healthcare; adult and combo vaccines expanding

now playing · Vaccines

ADCs and oligonucleotides unlock new cancer modalities with curative intent

Antibody-drug conjugates (biological missiles) and oligonucleotides (RNA spell-check) represent platform technologies enabling precision oncology; GSK's pipeline includes a multiple myeloma…

Vaccinestailwindscore 8/10emma walmsley

Vaccines offer highest ROI in healthcare; adult and combo vaccines expanding

Vaccines provide the best return on investment in healthcare after clean water; GSK is expanding into older adult vaccines (shingles, RSV, flu), developing combination vaccines using mRNA a…

AI in Healthcaretailwindscore 8/10emma walmsley

Healthcare data (1/3 of world's data) makes it the killer app for AI

A third of global data is healthcare-related, making the sector the premier use case for AI; tech companies view healthcare as the best case study for AI's societal impact, driving massive…

AI Drug Discoverytailwindscore 9/10emma walmsley

AI transforms pharma R&D from linear to loop, boosting hit rates

GSK is deploying AI and generative AI across the entire R&D value chain — target selection, molecule design, manufacturing, clinical trials — moving from a linear 90% failure model to a 'la…

GLP-1 & Metabolic Drugsmixedscore 7/10emma walmsley

Obesity drugs will reduce metabolic burden but neurodegeneration triples in 20 years

GLP-1 agonists will significantly reduce metabolic disease burden, but aging populations will triple the over-80 cohort in 20 years, making neurodegeneration (Alzheimer's, dementia) the nex…

Geopolitics & Trademixedscore 7/10emma walmsley

China accelerating first-in-class innovation; Europe risks regulatory drag

China's share of first-in-class drugs, clinical development speed, and approval pace are rising rapidly; GSK is actively in-licensing Chinese assets. Europe's strong regulators (EMA, MHRA)…

Antimicrobial Resistanceriskscore 7/10emma walmsley

AMR could kill 38M by 2050; new antibiotic models needed

Antimicrobial resistance is a 'slow pandemic' projected to kill 38 million by 2050; GSK has a large antibiotic pipeline including a first new UTI antibiotic in 20 years, and partners with t…

←